serum total fatty acids were estimated in controls and women using the oral contraceptives eugynon (containing 0.5 mg.of norgestron and 0.05 mg ethinyl oestradiol) and lyndiol (containing 2.5 mg. of linostrol and 0.05 mg of ethiny oestradiol) for periods ranging from 8 to 110 weeks. the serum total fatty acids level was found to be approximately 70% higher in the women using oral contraceptives...

BACKGROUND AND PURPOSE Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. METHODS A multicenter, population-based, case-control study was performed in 9 Dutch cent...

OBJECTIVE To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel. DESIGN Nested case-control and cohort study. SETTING The study was based on information from PharMetrics, a United States based company that collects information on claims paid by managed ...

background: polycystic ovary syndrome (pcos) is one of the common endocrine disorders in women of reproductive ages. it is associated with a range of disorders, such as dyslipidemia, hypertension, insulin resistance (ir), compensatory hyperinsulinemia,gestational, and type 2 diabetes, and increased risk of cardiovascular morbidity. there are different treatments available for pcos. the purpose ...

background polycystic ovarian syndrome (pcos) is the most common hormonal disorder in reproductive-age women. this syndrome is associated with many complications, so treatment of the disorder is usually warranted. objectives to evaluate the effects of a combined low-dose oral contraceptive (ld) and vitex agnus on the improvement of clinical and paraclinical parameters of pcos. methods this trip...

Current low dose OCs are highly effective with an excellent safety profile and many associated health benefits No single product has been shown to be superior in efficacy, safety or tolerability There is no "one size fits all" OC; different women may require different formulations Smoking particularly after age 35 with concurrent OC use greatly increases cardiovascular and thrombotic risks Age ...

BACKGROUND Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects approximately 10% of reproductive-aged women throughout their lives. Women with PCOS present with heterogeneous symptoms including ovulatory dysfunction, hyperandrogenism, and polycystic ovaries. Therefore, lifelong individualized management should be considered. Pharmacological agents commonly used to manage the symp...

To assess the effect of oral contraceptives on antinuclear antibodies (ANAs), rheumatoid factor (RF), and C-reactive protein (CRP), 3 groups of women were studied: 1) 174 women (ages 16-47) from the time of their initial uses of oral contraceptives, 2) 119 women (ages 17-39) selected from the community at random, and 3) 210 women (ages 17-47) who had been taking oral contraceptives prior to an...